Tumor-associated or tumor-specific antigen

Tumor-associated antigens and tumor-specific antigens are broad categories of molecules—typically proteins, peptides, or glycoproteins—that are present at higher levels in tumor cells compared to normal tissues or are uniquely mutated and expressed in cancer cells. Tumor-associated antigens (TAAs) are normal proteins overexpressed in cancer or appearing in developmental or germline tissues, while tumor-specific antigens (TSAs) are truly unique to tumor cells, often derived from mutations or viral oncogenes[1][2][4][5]. Neither “tumor-associated antigen” nor “tumor-specific antigen” designates a single molecule: they refer to large and partially overlapping families of targets, including cancer-testis antigens (e.g., MAGEA1, PRAME), differentiation antigens (e.g., CD20, PSA), oncofetal antigens (e.g., AFP, CEA), and neoantigens derived from somatic mutations[1][2][4][5][6]. Each specific antigen needs to be referenced individually to obtain precise clinical relevance; targeting these antigens has inspired many modern cancer immunotherapies, but true tumor specificity is rare and some are expressed at low levels in normal tissues, complicating safety and efficacy[1][4][3]. Key Clarification: - There is something incorrect or too broad about the entry “Tumor-associated or tumor-specific antigens”: it refers to a class/category, not a discrete drug target or molecular entity, and should be specified further for structured data use[1][2][3][4][5]. For structured records, each antigen (e.g., “Epidermal growth factor receptor,” “MAGEA3”) should have an individual entry.

Other names

Tumor antigenTAA (tumor-associated antigen)TSA (tumor-specific antigen)tumor markercancer/testis antigenoncofetal antigendifferentiation antigenneoantigen

- Immunotherapy (e.g., recognition by immune checkpoint inhibitors, T cell therapies, cancer vaccines) - Antibody-dependent cellular cytotoxicity (for some overexpressed antigens) - Other